Within our Pharmaceutical Development & Manufacturing framework, we operate a focused Drug Substance Development unit dedicated to complex biologics. As part of that unit, our Antibody-Drug Conjugate (ADC) Development services include a specialized track for bispecific ADC Development, concentrating on molecule engineering, conjugation readiness, and analytics during research-scale development.
Overview of Bispecific ADC Development
Bispecific ADCs combine dual antigen recognition with a conjugated cytotoxic modality to concentrate activity at preselected biological interfaces. Our role is to translate bispecific constructs into conjugation-ready materials with robust physicochemical attributes and traceable analytics suitable for scale-up enablement. We emphasize format selection (IgG-like vs. compact scaffolds), inter-arm affinity balance, valency architecture (1+1 or 2+1), and Fc engineering to support manufacturability, stability, and targeted internalization. We also establish orthogonal analytical methods that confirm identity, dual binding, structural integrity, and controlled heterogeneity.
Our Services
We provide below focuses strictly on bispecific ADC development—from format assessment and expression through characterization, stability, and scale-aware prototypes.
Bispecific Format Assessment Service
We evaluate IgG-like and non-IgG architectures (e.g., IgG-scFv, tandem diabody, 2+1 formats) for developability. Using sequence liabilities review, in silico risk screens, and small-panel expression pilots, we compare yield potential, predicted stability, and dual-binding geometry to recommend a tractable baseline format for subsequent development.
Expression & Material Supply Service
We produce research-grade bispecific antibody intermediates suitable for conjugation readiness and analytical method establishment. Activities include transient or small-scale stable expression, protein A (or alternative) capture, polishing tailored to bispecific heterogeneity, concentration/filtration, and documentation of batch genealogy.
Site Enablement & Conjugation Readiness Service
We prepare bispecific antibodies for downstream conjugation by establishing site-specificity enablers on the protein side—such as engineered cysteine placements or tag-based handles—while keeping linker–payload choices out of scope. Work includes site mapping, stress testing of engineered positions, and verification that modifications preserve dual binding and structural integrity.
Dual-Antigen Binding & Avidity Analytics Service
We implement tiered binding analytics to verify simultaneous or sequential engagement. Methods include single-analyte affinity measurements, dual-antigen competitive binding formats, avidity-sensitive assays, and internalization-surrogate readouts using model systems. We report kinetic and thermodynamic descriptors, stoichiometry trends, and retention of function after process manipulations.
Higher-Order Structure & Heterogeneity Control Service
We establish orthogonal methods (e.g., intact mass, subunit mapping, peptide mapping, charge and size variants profiling) to characterize chain pairing, mispairing risk, and aggregate/fragment content typical of bispecifics. We develop acceptance envelopes for research batches and define control levers (pH, buffer species, redox conditioning) to minimize product-related variants.
Our Bispecific ADC Portfolio
Our services support commonly adopted bispecific ADC categories and architectures:
- Tumor-Associated Antigen × Tumor-Associated Antigen (1+1 or 2+1): Dual engagement of co-expressed markers to enhance localization and internalization potential.
- Immune-Cell Engager × Tumor-Associated Antigen: Bispecifics configured for conditional immune synapse formation while preserving manufacturability attributes.
- Receptor × Co-Receptor (e.g., EGFR × MET; HER2 × HER3): Formats designed to address pathway redundancy with balanced affinities and controlled valency.
- Checkpoint-Ligand × Tumor-Associated Antigen: Constructs intended to couple microenvironmental binding with localized engagement, developed with stability and analytics at the forefront.
- Internalizing Receptor × Albumin-Binding Module: Architectures leveraging albumin interaction to adjust exposure profiles while maintaining conjugation readiness.
We deliver end-to-end Bispecific ADC Development within a disciplined drug-substance framework, emphasizing format assessment, conjugation readiness on the protein side, rigorous analytics, and stability knowledge. Contact us to align your program with a practical development path.
Our products and services are for research use only.
